Latest From Theramex
EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.
Amid ongoing manufacturing issues with its own HRT patches, women’s health spin-out Theramex acquires global rights to Janssen’s Evorel patches, also in shortage.
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
- Generic Drugs
- Therapeutic Areas
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Theramex SPA
- Western Europe
- Parent & Subsidiaries
- Senior Management
Anish Mehta, CEO
Ciarán Barr, CFO
Susanna El-Armale, SVP, Corp. Dev.
Timothy Kneen, EVP, Commercial Operations
Christophe Pelletier, EVP, Mktg. & Communication
- Contact Info
Sloane Square House
1 Holbein Place
London, SW1W 8NS